Hill Lucas, Smith Shawn R, Karris Maile Young
University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA,
Department of Medicine, University of California San Diego, San Diego, CA, USA.
HIV AIDS (Auckl). 2018 Oct 29;10:203-213. doi: 10.2147/HIV.S145529. eCollection 2018.
Modern pharmacologic management of people living with HIV involves the use of fixed dose combinations of antiretrovirals that are simple to take, well tolerated, and highly effective. Specific recent pharmacologic advancements include 1) the second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) that consistently show less side effects, high tolerability, minimal drug interactions, and rapid rates of HIV viral load decline and 2) tenofovir alafenamide, a prodrug of tenofovir that concentrates in lymphoid tissue and minimizes off target effects. Bictegravir/emtricitabine/tenofovir alafenamide or B/F/TAF is a recently approved fixed dose combination that incorporates these new advancements in the management of HIV. This review focuses on the data supporting the use of B/F/TAF, reviews clinically relevant findings, and highlights the unanswered questions that may limit its clinical utility.
现代对HIV感染者的药物治疗包括使用固定剂量的抗逆转录病毒药物组合，这些组合服用简便、耐受性良好且高效。近期具体的药物进展包括：1）第二代整合酶链转移抑制剂（多替拉韦和比克替拉韦），其始终显示出较少的副作用、高耐受性、最小的药物相互作用以及HIV病毒载量快速下降；2）替诺福韦艾拉酚胺，替诺福韦的前体药物，它集中在淋巴组织中并将脱靶效应降至最低。比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺（B/F/TAF）是最近批准的一种固定剂量组合，它将这些新进展纳入了HIV的治疗中。本综述重点关注支持使用B/F/TAF的数据，回顾临床相关发现，并突出可能限制其临床应用的未解决问题。
